Filing Details
- Accession Number:
- 0001209191-22-015131
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-02 21:00:35
- Reporting Period:
- 2022-02-28
- Accepted Time:
- 2022-03-02 21:00:35
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1658247 | Crinetics Pharmaceuticals Inc. | CRNX | Pharmaceutical Preparations (2834) | 263744114 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1807856 | Ajay Madan | C/O Crinetics Pharmaceuticals, Inc. 10222 Barnes Canyon Road, Bldg 2 San Diego CA 92121 | Chief Development Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-02-28 | 13,950 | $0.00 | 185,995 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2022-03-01 | 9,000 | $19.88 | 176,995 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Common Stock (right to buy) | Acquisiton | 2022-02-28 | 65,400 | $0.00 | 65,400 | $20.02 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
65,400 | 2032-02-27 | No | 4 | A | Direct |
Footnotes
- The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.
- The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
- The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.